Article Text

Download PDFPDF
Variant and clinical landscape of Leber hereditary optic neuropathy based on 1516 families with mtDNA variants in a tertiary centre
  1. Yuxi Zheng,
  2. Yingwei Wang,
  3. Yi Jiang,
  4. Junwen Wang,
  5. Shiqiang Li,
  6. Xueshan Xiao,
  7. Wenmin Sun,
  8. Panfeng Wang,
  9. Qingjiong Zhang,
  10. Xiaoyun Jia
  1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China
  1. Correspondence to Qingjiong Zhang; zhangqji{at}mail.sysu.edu.cn; Xiaoyun Jia; jiaxiaoyun{at}gzzoc.com

Abstract

Aims To investigate the clinical characteristics of Leber hereditary optic neuropathy (LHON) with mtDNA primary mutations to better understand features associated with prognosis.

Methods This study enrolled 1540 LHON patients from 1516 unrelated families genetically confirmed by Sanger or whole-mitochondrial sequencing between 1997 and 2022. The spectrum of variants was summarised and compared in different ethnic groups. Clinical data from outpatients were collected, including onset age, disease course, optic disc categories and the corresponding visual acuity.

Results Of the 1516 LHON families, 13 pathogenic mtDNA variants were detected, in which the proportion of m.11778G>A, m.3460G>A and m.3635G>A was significantly different from non-East Asians (p<0.0001). About 95% (1075/1131) of patients were between 8 and 40 years old at onset, with a median onset age of 16. The eyes of m.14484T>C patients presented with better visual acuity and slower progression across patients with different onset ages and initial severity. Eyes (N=439) with available fundus images were divided into four categories (C1–C4). The progression grades were derived from the category and the corresponding time course, where a higher grade (C3–C4 within 1 year) was associated with greater visual impairment than a lower grade (C1–C2 over 1 year) (p=4.60E-05) . A prognostic matrix showed that later onset and a higher progression grade are associated with higher risk of blindness.

Conclusion Compared with non-East Asians, Chinese LHON patients had higher proportions of m.11778G>A and m.3635G>A and lower m.3460G>A mutations. A novel progression grade derived from optic disc category was proposed. The prognostic matrix indicated that lower grade and younger-onset age are the most favourable prognostic factors.

  • Genetics
  • Optic Nerve

Data availability statement

No data are available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

No data are available.

View Full Text

Footnotes

  • Contributors XJ, XX, SL and QZ recruited the individuals diagnosed with different forms of ocular conditions. SL, XX, WS, XJ and QZ collected the clinical records. XJ performed the Sanger sequencing. PW performed the whole-mitochondrial sequencing. XJ and QZ designed the study. YZ conducted a statistical analysis. YZ, YW, YJ, JW, SL, XX, WS, QZ and XJ discussed the results. YZ and QZ wrote the manuscript. XJ and QZ responsible for the overall content as the guarantor. All authors reviewed and approved the manuscript for important intellectual content.

  • Funding National Natural Science Foundation of China (82171056) and the Science and Technology Planning Projects of Guangzhou (202102010271).

  • Disclaimer The sponsor or funding organisation had no role in the design or conduct of this research.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.